SEC Company Response from Theriva Biologics, Inc. (TOVX) (CIK 0000894158) (TOVX) — Apr 28, 2008
Theriva Biologics, Inc. (TOVX) (CIK 0000894158)
Date: April 28, 2008 · CIK: 0000894158 · Accession: 0000890163-08-000290
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-12584
Letter
VIA EDGAR AND United States Securities Attention: Sonia Barros Re: Pipex Pharmaceuticals, Inc. File No. 001-12584
Dear Ms. Barros:
Thank you for your April 25, 2008 letter regarding Pipex Pharmaceuticals, Inc.’s (the “Company”) proxy statement. We hereby submit a letter responding to the two comments. For your convenience, we have set forth below the comments in their entirety followed by our responses thereto.
1.
Please include the required compensation for 2006 in the summary compensation table.
Response: We will revise the summary compensation table to include the required compensation for 2006 in the Definitive Proxy Statement.
2.
Please disclose your current plans to complete a spin off. If you have any plans to complete a spin off, you must provide all information that would be required as if the shareholders were voting on a spin off. See Note A to Schedule 14A.
United States Securities
and Exchange Commission
April 28, 2008
Page 2
Response: We will disclose in the Definitive Proxy Statement that “the Company has no plans to complete a spin off at this time.”
Please call me at (516)222-0888 to let me know whether I can file the Definitive Proxy Statement.
Thank you
Sincerely,
/s/ Steven Pappas
Show Raw Text
CORRESP
1
filename1.htm
LEHMAN & EILEN LLP
50 Charles Lindbergh Blvd
Suite 505
Uniondale, NY 11553
Tel: (516) 222-0888
Fax: (516) 222-0915
April 28, 2008
VIA EDGAR AND
OVERNIGHT MAIL
United States Securities
and Exchange Commission
100 F Street, NE
Mail Stop 4561
Washington, D.C. 20549
Attention: Sonia Barros
Re:
Pipex Pharmaceuticals, Inc.
File No. 001-12584
Dear Ms. Barros:
Thank you for your April 25, 2008 letter regarding Pipex Pharmaceuticals, Inc.’s (the “Company”) proxy statement. We hereby submit a letter responding to the two comments. For your convenience, we have set forth below the comments in their entirety followed by our responses thereto.
1.
Please include the required compensation for 2006 in the summary compensation table.
Response: We will revise the summary compensation table to include the required compensation for 2006 in the Definitive Proxy Statement.
2.
Please disclose your current plans to complete a spin off. If you have any plans to complete a spin off, you must provide all information that would be required as if the shareholders were voting on a spin off. See Note A to Schedule 14A.
United States Securities
and Exchange Commission
April 28, 2008
Page 2
Response: We will disclose in the Definitive Proxy Statement that “the Company has no plans to complete a spin off at this time.”
Please call me at (516)222-0888 to let me know whether I can file the Definitive Proxy Statement.
Thank you
Sincerely,
/s/ Steven Pappas
Steven Pappas
cc: Pipex Pharmaceuticals, Inc.